News

The companies have reached settlement more than five years after the litigation started with Xarelto. During the period, all six cases related to Xarelto went to trial. Bayer

The trial, called ARTEMIS, demonstrated that the proportion of patients treated with AR101 who could tolerate a 1,000mg dose of peanut protein, was significantly higher than what was

The Company plans to use the proceeds from this financing to advance its anti-CD47 antibody AO-176’s ongoing Phase 1 clinical trial in select solid tumors, as well as

“Today’s submission brings us one step closer to our goal of improving treatment outcomes for people newly diagnosed with multiple myeloma,” said José Antonio Burón Vidal, VP Medical

Owned by Ampersand Capital Partners, Brammer Bio is engaged in the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.

Gov. Roy Cooper, Secretary of Commerce Tony Copeland and local patient advocates will join chief bluebird Nick Leschly in a ribbon cutting ceremony at the 125,000-square-foot facility. Currently,

The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement with no worsening of steatohepatitis compared with placebo at week 72. “Although emricasan did not have the

The further positive data from the DREAMM-1 study, which is based on results of the pre-specified interim analysis, showed the durability and depth of response of GSK2857916 anti-BCMA

Other investors participating in the round include existing investors Frazier Healthcare Partners, Amgen Ventures, and MRL Ventures Fund as well as HighLight Capital, Pharmaron and Greenspring Associates. Dr.